Research Article
Chimeric Antigen Receptor T-Cell Therapy: What the Neuroradiologist Needs to Know
H.A. Valand, F. Huda and R.K. Tu
American Journal of Neuroradiology May 2019, 40 (5) 766-768; DOI: https://doi.org/10.3174/ajnr.A6042
H.A. Valand
aFrom the American University of Integrative Sciences (H.A.V.), Brampton, Ontario, Canada
F. Huda
bDepartment of Radiology (F.H.), George Washington University Hospital, Washington, DC
R.K. Tu
cProgressive Radiology (R.K.T.), George Washington University, Washington, DC.

Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
American Journal of Neuroradiology
Vol. 40, Issue 5
1 May 2019
Advertisement
H.A. Valand, F. Huda, R.K. Tu
Chimeric Antigen Receptor T-Cell Therapy: What the Neuroradiologist Needs to Know
American Journal of Neuroradiology May 2019, 40 (5) 766-768; DOI: 10.3174/ajnr.A6042
Jump to section
- Article
- Abstract
- ABBREVIATIONS:
- What are Chimeric Antigen Receptor T-Cells?
- Who Benefits from CAR T-Cell Therapy?
- How Is CAR T-Cell Therapy Delivered to Patients?
- What Are the Major Toxicities of CAR T-Cell Therapy and How Are They Graded?
- What Are the Neuroradiologic Findings in Patients Receiving CAR T-Cell Therapy?
- What are the Neuroradiologic Recommendations in Patients Receiving CAR T-Cell Therapy?
- What Are the Challenges in Implementing CAR T-Cell Therapy?
- REFERENCES
- Info & Metrics
- Responses
- References
Related Articles
- No related articles found.
Cited By...
This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.
Similar Articles
Advertisement